VastCon was founded in 2011 by Drs. Anuraag Shrivastav and Shailly Varma Shrivastav and is headquartered in Winnipeg, Manitoba, Canada. The company includes a team of basic research scientists with the mandate to take research from the laboratory to bedside.
VastCon’s lead product is a novel blood test for the early detection and screening of colorectal cancer. Colorectal cancer is the second or third leading cause of death due to cancer world-wide, despite being one of the most curable cancers if detected early. Unfortunately for many people, by the time it is detected it is already at an advanced stage leading to death.
Population-based screening tests currently available in the market include FOBT, FIT and stool DNA test. These test all require the collection of feces, and as a result, the test compliance rates are low. There is an urgent unmet need to develop a technology that uses blood for the detection of colorectal cancer. VastCon’s lead technology is a novel blood test for early detection and screening of colorectal cancer. This technology is based on the discovery of two biomarkers that are present in high concentrations in the peripheral blood of CRC patients and not healthy subjects. In an initial preclinical study the company found that the test was highly sensitive and specific to colorectal cancer.
VastCon’s aim is to grow into a multinational company developing diagnostics for cancers of many types.